Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

Autor: Mila S. Griffioen, David C. de Leeuw, Jeroen J. W. M. Janssen, Linda Smit

Publikováno v: Griffioen, M S, de Leeuw, D C, Janssen, J J W M & Smit, L 2022, ' Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies ', Cancers, vol. 14, no. 14, 3456 . https://doi.org/10.3390/cancers14143456

Venetoclax is a BCL-2 inhibitor that effectively improves clinical outcomes in newly diagnosed, relapsed and refractory acute myeloid leukemia (AML) patients, with complete response rates (with and without complete blood count recovery) ranging betwe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f5469dbb9dc05ece7950f612302a682
https://doi.org/10.3390/cancers14143456